Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 12/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 11/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | PAK4 | O96013 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16675904 | 0.91 | GRM4 (0.40) | PLK4NTRK1NPC1RAB9AGRM4 | |
| SCHEMBL16675906 | 0.91 | NPC1 (0.36) | PLK4NTRK1NPC1RAB9AGRM4 | |
| SCHEMBL18556908 | 0.88 | CYP2D6 (0.44) | PLK4NTRK1GRM4CCNE1CDK2 | |
| SCHEMBL16675909 | 0.84 | PAK4 (0.39) | PLK4NTRK1PAK4JAK3 | |
| SCHEMBL16675953 | 0.81 | GSK3B (0.39) | — | |
| SCHEMBL16675894 | 0.81 | RAB9A (0.39) | NPC1RAB9AGRM4CDK2CYP2D6 | |
| SCHEMBL16675898 | 0.81 | NPC1 (0.39) | PLK4NTRK1NPC1RAB9AGRM4 | |
| SCHEMBL16675918 | 0.80 | GRM4 (0.43) | PLK4NTRK1NPC1RAB9AGRM4 | |
| SCHEMBL16675930 | 0.80 | JAK3 (0.37) | CCNE1CDK2JAK3 | |
| SCHEMBL16675913 | 0.79 | GRM4 (0.42) | NPC1RAB9AGRM4CDK2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | ATP5F1A, ATP5F1D, ATP5F1C | PLK4 3395/4885NTRK1 4595/4885NPC1 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.